The European Medicines Agency has approved Ozempic for slowing kidney disease progression by 24% in a large-scale clinical trial. This is expected to expand its utilization in patients at high risk of kidney failure, but the high cost may limit accessibility.
image sourced from original article at https://www.ynetnews.com/health_science/article/sjoahr6v1eOriginal article source: https://www.ynetnews.com/health_science/article/sjoahr6v1e
Source Id: 8460585202
